Since EBV infection itself is thought to be associated with some autoimmune diseases such as multiple sclerosis [25], PD-L1-targeted therapy of EBVaGC, which might induce EBV reactivation and cellular lysis, should be performed with special caution for immune-related adverse events. The gene discussed is CD274; the disease is autoimmune disease.